PMID- 33567529 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240331 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 13 IP - 4 DP - 2021 Feb 8 TI - Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer. LID - 10.3390/cancers13040677 [doi] LID - 677 AB - BACKGROUND: Bone metastatic prostate cancer (BMPCa), despite the initial responsiveness to androgen deprivation therapy (ADT), inevitably becomes resistant. Recent clinical trials with upfront treatment of ADT combined with chemotherapy or novel hormonal therapies (NHTs) have extended overall patient survival. These results indicate that there is significant potential for the optimization of standard-of-care therapies to delay the emergence of progressive metastatic disease. METHODS: Here, we used data extracted from human bone metastatic biopsies pre- and post-abiraterone acetate/prednisone to generate a mathematical model of bone metastatic prostate cancer that can unravel the treatment impact on disease progression. Intra-tumor heterogeneity in regard to ADT and chemotherapy resistance was derived from biopsy data at a cellular level, permitting the model to track the dynamics of resistant phenotypes in response to treatment from biological first-principles without relying on data fitting. These cellular data were mathematically correlated with a clinical proxy for tumor burden, utilizing prostate-specific antigen (PSA) production as an example. RESULTS: Using this correlation, our model recapitulated the individual patient response to applied treatments in a separate and independent cohort of patients (n = 24), and was able to estimate the initial resistance to the ADT of each patient. Combined with an intervention-decision algorithm informed by patient-specific prediction of initial resistance, we propose to optimize the sequence of treatments for each patient with the goal of delaying the evolution of resistant disease and limit cancer cell growth, offering evidence for an improvement against retrospective data. CONCLUSIONS: Our results show how minimal but widely available patient information can be used to model and track the progression of BMPCa in real time, offering a clinically relevant insight into the patient-specific evolutionary dynamics of the disease and suggesting new therapeutic options for intervention. TRIAL REGISTRATION: NCT # 01953640. FUNDING: Funded by an NCI U01 (NCI) U01CA202958-01 and a Moffitt Team Science Award. CCL and DB were partly funded by an NCI PSON U01 (U01CA244101). AA was partly funded by a Department of Defense Prostate Cancer Research Program (W81XWH-15-1-0184) fellowship. LC was partly funded by a postdoctoral fellowship (PF-13-175-01-CSM) from the American Cancer Society. FAU - Araujo, Arturo AU - Araujo A AUID- ORCID: 0000-0002-0269-2819 AD - Integrated Mathematical Oncology Department, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. AD - School of Arts, University of Roehampton, London SW15 5PU, UK. AD - Department of Computer Science, University College London, London WC1E 6BT, UK. FAU - Cook, Leah M AU - Cook LM AD - Fred & Pamela Buffett Cancer Center, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA. FAU - Frieling, Jeremy S AU - Frieling JS AD - Department of Tumor Biology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. FAU - Tan, Winston AU - Tan W AD - Department of Medical Oncology Mayo Clinic, Jacksonville, FL 32224, USA. FAU - Copland, John A 2nd AU - Copland JA 2nd AD - Cancer Biology, Mayo Clinic, Jacksonville, FL 32224, USA. FAU - Kohli, Manish AU - Kohli M AUID- ORCID: 0000-0002-9735-6614 AD - Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84122, USA. FAU - Gupta, Shilpa AU - Gupta S AD - Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA. FAU - Dhillon, Jasreman AU - Dhillon J AD - Genitourinary Oncology Department, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. FAU - Pow-Sang, Julio AU - Pow-Sang J AD - Genitourinary Oncology Department, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. FAU - Lynch, Conor C AU - Lynch CC AD - Department of Tumor Biology, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. AD - Genitourinary Oncology Department, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. FAU - Basanta, David AU - Basanta D AUID- ORCID: 0000-0002-8527-0776 AD - Integrated Mathematical Oncology Department, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. AD - Genitourinary Oncology Department, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. LA - eng GR - U01CA202958-01/NH/NIH HHS/United States GR - U01CA244101/NH/NIH HHS/United States PT - Journal Article DEP - 20210208 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC7915310 OTO - NOTNLM OT - androgen therapy resistance OT - bone metastatic prostate cancer OT - computational model OT - mathematical oncology OT - personalized treatment COIS- The authors declare no conflict of interest. EDAT- 2021/02/12 06:00 MHDA- 2021/02/12 06:01 PMCR- 2021/02/08 CRDT- 2021/02/11 01:00 PHST- 2020/12/18 00:00 [received] PHST- 2021/01/28 00:00 [revised] PHST- 2021/02/02 00:00 [accepted] PHST- 2021/02/11 01:00 [entrez] PHST- 2021/02/12 06:00 [pubmed] PHST- 2021/02/12 06:01 [medline] PHST- 2021/02/08 00:00 [pmc-release] AID - cancers13040677 [pii] AID - cancers-13-00677 [pii] AID - 10.3390/cancers13040677 [doi] PST - epublish SO - Cancers (Basel). 2021 Feb 8;13(4):677. doi: 10.3390/cancers13040677.